Diagnosis of asthma in children
BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39234.651412.AE (Published 26 July 2007) Cite this as: BMJ 2007;335:198- J Townshend, registrar in respiratory paediatrics,
- S Hails, paediatric respiratory nurse specialist,
- M Mckean, consultant in respiratory paediatrics
- Paediatric Respiratory Unit, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP
- Correspondence to: M Mckeanm.c.mckean{at}ncl.ac.uk
- Accepted 29 May 2007
Summary points
“Childhood asthma” describes several different clinical phenotypes with different management strategies
The two most common phenotypes are atopic asthma, more common in school aged children, and episodic viral wheeze, more common in preschool children
Wheeze is a poorly understood symptom, and parents should be asked to clarify what they understand it to be
Wheeze is commonly associated with asthma, but several other conditions can result in recurrent wheezing and should be considered before a diagnosis is made
If it's wheeze it must be asthma, and if it's asthma it must mean bronchodilators and inhaled corticosteroids—simple enough. Indeed, as asthma is so common this paradigm might seem to be logical. The large scale international study of asthma and allergy in childhood (ISAAC) found that the United Kingdom, Australia, and New Zealand had among the highest prevalences, with 15% of children affected.1 Asthma is more complicated, however, especially in children. We are often uncertain whether children who wheeze do have asthma, and some people say that diagnosing asthma in very young children is not possible. An increasing body of evidence suggests that asthma is a complex disorder and that different patterns of illness have different underlying pathogenesis.
Many studies have investigated various treatments in older children with classic allergic asthma, yet relatively few have considered the many young children who have recurrent wheeze. Many common treatments now have a good evidence base, but gaps still exist, such as treatments for the most difficult and severe childhood asthma. Therapeutic advances include both new drugs and new licences for older drugs. For example, the new drug omalizumab and montelukast are now licensed down to 6 months of age. Yet despite …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.